
Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS – Free Report) – Stock analysts at HC Wainwright reduced their Q4 2026 EPS estimates for Pelthos Therapeutics in a research note issued on Friday, November 13th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of ($4.93) for the quarter, down from their previous forecast of ($4.71). The consensus estimate for Pelthos Therapeutics’ current full-year earnings is ($15.22) per share. HC Wainwright also issued estimates for Pelthos Therapeutics’ FY2027 earnings at ($11.34) EPS, FY2028 earnings at ($4.22) EPS, FY2029 earnings at ($1.80) EPS and FY2030 earnings at $1.45 EPS.
Other equities research analysts also recently issued research reports about the stock. Alliance Global Partners downgraded shares of Pelthos Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday. Zacks Research raised shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 4th. Oppenheimer cut their price target on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a report on Friday, August 14th. Lake Street Capital reduced their price objective on shares of Pelthos Therapeutics from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, October 12th. Finally, Piper Sandler reissued an “overweight” rating and issued a $21.00 price objective (down from $48.00) on shares of Pelthos Therapeutics in a research note on Friday. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $48.33.
Check Out Our Latest Stock Report on PTHS
Pelthos Therapeutics Stock Down 3.9%
Shares of NYSEAMERICAN PTHS opened at $7.15 on Tuesday. The business’s 50 day moving average is $17.82 and its two-hundred day moving average is $23.36. The company has a debt-to-equity ratio of 3.40, a current ratio of 1.98 and a quick ratio of 1.31. Pelthos Therapeutics has a 1-year low of $7.12 and a 1-year high of $34.68.
Pelthos Therapeutics (NYSEAMERICAN:PTHS – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($2.04) earnings per share for the quarter, beating the consensus estimate of ($2.83) by $0.79. Pelthos Therapeutics had a negative return on equity of 288.77% and a negative net margin of 123.24%. The business had revenue of $15.39 million during the quarter.
Institutional Investors Weigh In On Pelthos Therapeutics
An institutional investor recently raised its stake in Pelthos Therapeutics stock. Pale Fire Capital SE lifted its holdings in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS – Free Report) by 59.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,919 shares of the company’s stock after purchasing an additional 4,819 shares during the quarter. Pale Fire Capital SE owned about 0.38% of Pelthos Therapeutics worth $271,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 77.96% of the company’s stock.
Pelthos Therapeutics Company Profile
Pelthos Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for dermatologic conditions. Its portfolio includes ZELSUVMI (berdazimer) topical gel, an FDA-approved prescription treatment for molluscum contagiosum, a viral skin infection. ZELSUVMI is approved in the United States for adults and children aged one year and older. The topical treatment is designed for application at home, providing an option for patients and caregivers managing the condition.
See Also
- Five stocks we like better than Pelthos Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Pelthos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pelthos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
